Multiple Myeloma News & Features
Bortezomib-based vs non-bortezomib-based post-transplantation treatment in multiple myeloma patients: a systematic review and meta-analysis of Phase III randomized controlled trials
[Oncotargets and Therapy] This research examines the efficacy and safety of bortezomib-based vs non-bortezomib-based post-transplantation therapy in patients with multiple myeloma.
Researchers have found that spending more leisure time sitting was associated with an increased risk for developing cancer in women.
Patients with relapsed or refractory myeloma experience the most benefit from panobinostat plus bortezomib and dexamethasone.
Researchers have reported safely using immune cells grown from patients' own bone marrow to treat multiple myeloma, according to clinical trial data.
Addition of elotuzumab significantly reduced risk of disease progression in relapsed or refractory multiple myeloma.
Multiple Myeloma Clinical Trials
- Universal health literacy precautions recommended to assist patient understanding
- Likelihood of lung cancer screening update
- Generic meds may boost survival in some early breast cancers
- Bortezomib-based vs non-bortezomib-based post-transplantation treatment in multiple myeloma patients: a systematic review and meta-analysis of Phase III randomized controlled trials
- New program using CT technology helping to better detect lung cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|